KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Long-Term Investments (2016 - 2025)

AbbVie (ABBV) has disclosed Long-Term Investments for 14 consecutive years, with $268.0 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 3.94% to $268.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $268.0 million through Dec 2025, down 3.94% year-over-year, with the annual reading at $268.0 million for FY2025, 3.94% down from the prior year.
  • Long-Term Investments for Q4 2025 was $268.0 million at AbbVie, down from $291.0 million in the prior quarter.
  • The five-year high for Long-Term Investments was $310.0 million in Q2 2025, with the low at $235.0 million in Q3 2022.
  • Average Long-Term Investments over 5 years is $275.2 million, with a median of $273.5 million recorded in 2021.
  • The sharpest move saw Long-Term Investments soared 291.03% in 2021, then decreased 14.75% in 2022.
  • Over 5 years, Long-Term Investments stood at $277.0 million in 2021, then fell by 13.0% to $241.0 million in 2022, then increased by 26.14% to $304.0 million in 2023, then dropped by 8.22% to $279.0 million in 2024, then fell by 3.94% to $268.0 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $268.0 million, $291.0 million, and $310.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.